The DOI matches its Crossref record; 633 of the 633 references it cites were found in a registry or an index.
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Open accessAbstract
Autoimmune disorders are characterized by aberrant T cell and B cell reactivity to the body’s own components, resulting in tissue destruction and organ dysfunction. Autoimmune diseases affect a wide range of people in many parts of the world and have become one of the major concerns in public health. In recent years, there have been substantial progress in our understanding of the epidemiology, risk factors, pathogenesis and mechanisms of autoimmune diseases. Current approved therapeutic interventions for autoimmune diseases are mainly non-specific immunomodulators and may cause broad immunosuppression that leads to serious adverse effects. To overcome the limitations of immunosuppressive drugs in treating autoimmune diseases, precise and target-specific strategies are urgently needed. To date, significant advances have been made in our understanding of the mechanisms of immune tolerance, offering a new avenue for developing antigen-specific immunotherapies for autoimmune diseases. These antigen-specific approaches have shown great potential in various preclinical animal models and recently been evaluated in clinical trials. This review describes the common epidemiology, clinical manifestation and mechanisms of autoimmune diseases, with a focus on typical autoimmune diseases including multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and sjögren’s syndrome. We discuss the current therapeutics developed in this field, highlight the recent advances in the use of nanomaterials and mRNA vaccine techniques to induce antigen-specific immune tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 12×
“100 Besides, another large genetic research established a reference map about susceptibility genes of MS based on big data processing, which includes 200 autosomal susceptibility variants outside the MHC region, 32 variants in the MHC region and 1 variant in chromosome X. 101 The MS risk-related gene map can help us t…”
InfluentialEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“529,530 Due to the precise targeting mechanism, researchers have tried to promote it to other fi elds such as autoimmune disease treatment 531 – 534 (Fig.”
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 3×
“556 CRS is the most prevalent adverse effect after CAR-T therapy which can manifest as a strong immune activation and powerful in fl ammatory storm.”
BackgroundKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40930 · Cited by 2,677
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520970841 · Cited by 2,653
Gregersen, P. K., Silver, J., & Winchester, R. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301102 · Cited by 2,599
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Regulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260 · cited 1×
“522,523 These characteristics of EVs are extremely useful for antigen-speci fi c therapy.”
BackgroundImmunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Bjornevik, K., Cortese, M., Healy, B. C., Kuhle, J., Mina, M. J., Leng, Y., Elledge, S. J., Niebuhr, D. W., Scher, A. I., Munger, K. L., et al. (2022) · Science · doi:10.1126/science.abj8222 · Cited by 2,049 · cited 1×
“104 The mechanism of EBV infection to cause MS is still not clear, current studies suggest the role of molecular mimicry mentioned above in causing the break of immune tolerance and the development of autoimmune disorders.”
BackgroundExpansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis
Scher, J. U., Sczesnak, A., Longman, R. S., Segata, N., Ubeda, C., Bielski, C., Rostron, T., Cerundolo, V., Pamer, E. G., Abramson, S. B., et al. (2013) · eLife · doi:10.7554/elife.01202 · Cited by 2,047
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Genetic and epigenetic fine mapping of causal autoimmune disease variants
Farh, K. K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W. J., Beik, S., Shoresh, N., Whitton, H., Ryan, R. J. H., Shishkin, A. A., et al. (2015) · Nature · doi:10.1038/nature13835 · Cited by 1,956
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,948
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Fox, R. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66990-5 · Cited by 1,828
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium, Patsopoulos, N. A., Baranzini, S. E., Santaniello, A., Shoostari, P., Cotsapas, C., Wong, G., Beecham, A. H., James, T., Replogle, J., et al. (2019) · Science · doi:10.1126/science.aav7188 · Cited by 1,818
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109927 · Cited by 1,816
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
Safiri, S., Kolahi, A.-A., Smith, E., Hill, C., Bettampadi, D., Mansournia, M. A., Hoy, D., Ashrafi-Asgarabad, A., Sepidarkish, M., Almasi-Hashiani, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216515 · Cited by 1,651
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Klareskog, L., Stolt, P., Lundberg, K., Källberg, H., Bengtsson, C., Grunewald, J., Rönnelid, J., Erlandsson Harris, H., Ulfgren, A., Rantapää‐Dahlqvist, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21575 · Cited by 1,515
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012
Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., Linder, B., Marcovina, S., Pettitt, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610187 · Cited by 1,476
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative Approaches
Constant, S. L., & Bottomly, K. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.297 · Cited by 1,459
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 1×
“292 ,293 In 2018, the FDA approved the fi rst liposome complex for siRNA binding (Patisiran) for the treatment of a rare disease called hereditary transthyretin-mediated amyloidosis (hATTR).”
BackgroundKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro
Selmaj, K. W., & Raine, C. S. (1988) · Annals of Neurology · doi:10.1002/ana.410230405 · Cited by 1,368
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Differential T Cell Costimulatory Requirements in CD28-Deficient Mice
Shahinian, A., Pfeffer, K., Lee, K. P., Kündig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B., & Mak, T. W. (1993) · Science · doi:10.1126/science.7688139 · Cited by 1,257
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Berer, K., Mues, M., Koutrolos, M., Rasbi, Z. A., Boziki, M., Johner, C., Wekerle, H., & Krishnamoorthy, G. (2011) · Nature · doi:10.1038/nature10554 · Cited by 1,251
An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis
BRENNER, S., JACOB, F., & MESELSON, M. (1961) · Nature · doi:10.1038/190576a0 · Cited by 1,234
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., McDevitt, H., Bonyhadi, M., & Bluestone, J. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040139 · Cited by 1,221
Extracellular vesicles as drug delivery systems: Why and how?
Elsharkasy, O. M., Nordin, J. Z., Hagey, D. W., de Jong, O. G., Schiffelers, R. M., Andaloussi, S. E., & Vader, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.004 · Cited by 1,197
Induction and molecular signature of pathogenic TH17 cells
Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D. A., et al. (2012) · Nature Immunology · doi:10.1038/ni.2416 · Cited by 1,174
Human autoimmune diseases: a comprehensive update
Wang, L., Wang, F., & Gershwin, M. E. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12395 · Cited by 1,168
Gregory, G. A., Robinson, T. I. G., Linklater, S. E., Wang, F., Colagiuri, S., de Beaufort, C., Donaghue, K. C., Harding, J. L., Wander, P. L., Zhang, X., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00218-2 · Cited by 1,149
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis
Rao, D. A., Gurish, M. F., Marshall, J. L., Slowikowski, K., Fonseka, C. Y., Liu, Y., Donlin, L. T., Henderson, L. A., Wei, K., Mizoguchi, F., et al. (2017) · Nature · doi:10.1038/nature20810 · Cited by 1,125 · cited 1×
“180 Besides, some CD8 + GZMK + T cells also appear to generate IFN-γ .”
BackgroundKawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., Kishimoto, T., & Kikutani, H. (1994) · Immunity · doi:10.1016/1074-7613(94)90095-7 · Cited by 1,108
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Metalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,042
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Effects of tobacco smoke on immunity, inflammation and autoimmunity
Arnson, Y., Shoenfeld, Y., & Amital, H. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.12.003 · Cited by 967
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., & Tedder, T. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36030 · Cited by 913
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Conrad, N., Misra, S., Verbakel, J. Y., Verbeke, G., Molenberghs, G., Taylor, P. N., Mason, J., Sattar, N., McMurray, J. J. V., McInnes, I. B., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00457-9 · Cited by 879
Diet, metabolites, and “western-lifestyle” inflammatory diseases
Thorburn, A. N., Macia, L., & Mackay, C. R. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.014 · Cited by 879
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 873
Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future
Arvizo, R. R., Bhattacharyya, S., Kudgus, R. A., Giri, K., Bhattacharya, R., & Mukherjee, P. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15355f · Cited by 866
Di Matteo, A., Bathon, J. M., & Emery, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01525-8 · Cited by 849
Safiri, S., Kolahi, A. A., Hoy, D., Smith, E., Bettampadi, D., Mansournia, M. A., Almasi-Hashiani, A., Ashrafi-Asgarabad, A., Moradi-Lakeh, M., Qorbani, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215920 · Cited by 842
Translocation of a gut pathobiont drives autoimmunity in mice and humans
Manfredo Vieira, S., Hiltensperger, M., Kumar, V., Zegarra-Ruiz, D., Dehner, C., Khan, N., Costa, F. R. C., Tiniakou, E., Greiling, T., Ruff, W., et al. (2018) · Science · doi:10.1126/science.aar7201 · Cited by 839
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Kiriakidou, M., & Ching, C. L. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202006020 · Cited by 821
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820
Antigen-presenting cell function in the tolerogenic liver environment
Thomson, A. W., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2858 · Cited by 805
HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk
Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M., Concannon, P., Mychaleckyj, J. C., Todd, J. A., Bonella, P., Fear, A. L., et al. (2008) · Diabetes · doi:10.2337/db07-1331 · Cited by 790
Dendrou, C. A., Petersen, J., Rossjohn, J., & Fugger, L. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.143 · Cited by 787
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Hyperbranched polymers: advances from synthesis to applications
Zheng, Y., Li, S., Weng, Z., & Gao, C. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00528g · Cited by 765
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
Gravallese, E. M., & Firestein, G. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2103726 · Cited by 752
Viral evasion and subversion of pattern-recognition receptor signalling
Bowie, A. G., & Unterholzner, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2436 · Cited by 746
Tarbell, K. V., Yamazaki, S., Olson, K., Toy, P., & Steinman, R. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040180 · Cited by 738
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Ellebrecht, C. T., Bhoj, V. G., Nace, A., Choi, E. J., Mao, X., Cho, M. J., Di Zenzo, G., Lanzavecchia, A., Seykora, J. T., Cotsarelis, G., et al. (2016) · Science · doi:10.1126/science.aaf6756 · Cited by 738
Global epidemiology of rheumatoid arthritis
Finckh, A., Gilbert, B., Hodkinson, B., Bae, S.-C., Thomas, R., Deane, K. D., Alpizar-Rodriguez, D., & Lauper, K. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00827-y · Cited by 736
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Mechanisms, Applications, and Challenges of Insect RNA Interference
Zhu, K. Y., & Palli, S. R. (2020) · Annual Review of Entomology · doi:10.1146/annurev-ento-011019-025224 · Cited by 709
Global epidemiology of systemic lupus erythematosus
Barber, M. R. W., Drenkard, C., Falasinnu, T., Hoi, A., Mak, A., Kow, N. Y., Svenungsson, E., Peterson, J., Clarke, A. E., & Ramsey-Goldman, R. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00668-1 · Cited by 709
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Mariño, E., Richards, J. L., McLeod, K. H., Stanley, D., Yap, Y. A., Knight, J., McKenzie, C., Kranich, J., Oliveira, A. C., Rossello, F. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3713 · Cited by 686 · cited 1×
“46,47 The nutrition change in some Western countries coincides with the rise in autoimmune diseases.”
BackgroundSimpson, N., Gatenby, P. A., Wilson, A., Malik, S., Fulcher, D. A., Tangye, S. G., Manku, H., Vyse, T. J., Roncador, G., Huttley, G. A., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25032 · Cited by 684
Sloan-Lancaster, J., & Allen, P. M. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.1 · Cited by 676
Furman, D., Hejblum, B. P., Simon, N., Jojic, V., Dekker, C. L., Thiébaut, R., Tibshirani, R. J., & Davis, M. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321060111 · Cited by 673
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study
Harjutsalo, V., Sjöberg, L., & Tuomilehto, J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60765-5 · Cited by 666
The immunological anatomy of the skin
Kabashima, K., Honda, T., Ginhoux, F., & Egawa, G. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0084-5 · Cited by 650
Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Activation‐induced cell death in T cells
Green, D. R., Droin, N., & Pinkoski, M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00051.x · Cited by 647
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions
Yoshizaki, A., Miyagaki, T., DiLillo, D. J., Matsushita, T., Horikawa, M., Kountikov, E. I., Spolski, R., Poe, J. C., Leonard, W. J., & Tedder, T. F. (2012) · Nature · doi:10.1038/nature11501 · Cited by 634
Molecular mimicry and autoimmunity
Rojas, M., Restrepo-Jiménez, P., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Leung, P. S. C., Ansari, A. A., Gershwin, M. E., & Anaya, J.-M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.012 · Cited by 627
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Locally renewing resident synovial macrophages provide a protective barrier for the joint
Culemann, S., Grüneboom, A., Nicolás-Ávila, J. Á., Weidner, D., Lämmle, K. F., Rothe, T., Quintana, J. A., Kirchner, P., Krljanac, B., Eberhardt, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1471-1 · Cited by 625
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107725 · Cited by 610
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
A functional and structural basis for TCR cross-reactivity in multiple sclerosis
Lang, H. L. E., Jacobsen, H., Ikemizu, S., Andersson, C., Harlos, K., Madsen, L., Hjorth, P., Sondergaard, L., Svejgaard, A., Wucherpfennig, K., et al. (2002) · Nature Immunology · doi:10.1038/ni835 · Cited by 591
Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis
Weiner, H. L., Mackin, G. A., Matsui, M., Orav, E. J., Khoury, S. J., Dawson, D. M., & Hafler, D. A. (1993) · Science · doi:10.1126/science.7680493 · Cited by 584
Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23279 · Cited by 579
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
DEMANUELE, A., & ATTWOOD, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.012 · Cited by 571
Novel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Plenge, R. M., Padyukov, L., Remmers, E. F., Purcell, S., Lee, A. T., Karlson, E. W., Wolfe, F., Kastner, D. L., Alfredsson, L., Altshuler, D., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/498651 · Cited by 564
Lövgren, T., Eloranta, M., Båve, U., Alm, G. V., & Rönnblom, L. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20254 · Cited by 552
Machado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
Mechanisms of central tolerance for B cells
Nemazee, D. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.19 · Cited by 539
Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria
Wells, J. M., & Mercenier, A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1840 · Cited by 537
Regulatory mechanisms in T cell receptor signalling
Gaud, G., Lesourne, R., & Love, P. E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0020-8 · Cited by 532
for UK Primary Sjögren's Syndrome Registry, Lessard, C. J., Li, H., Adrianto, I., Ice, J. A., Rasmussen, A., Grundahl, K. M., Kelly, J. A., Dozmorov, M. G., Miceli-Richard, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2792 · Cited by 529
Notch signalling drives synovial fibroblast identity and arthritis pathology
Wei, K., Korsunsky, I., Marshall, J. L., Gao, A., Watts, G. F. M., Major, T., Croft, A. P., Watts, J., Blazar, P. E., Lange, J. K., et al. (2020) · Nature · doi:10.1038/s41586-020-2222-z · Cited by 528
Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40137 · Cited by 527
T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis
Critchfield, J. M., Racke, M. K., Zúñiga-Pflücker, J. C., Cannella, B., Raine, C. S., Goverman, J., & Lenardo, M. J. (1994) · Science · doi:10.1126/science.7509084 · Cited by 524
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, Ö., Kranz, L. M., Berger, H., Petschenka, J., et al. (2021) · Science · doi:10.1126/science.aay3638 · Cited by 520
Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L., Comi, G., Kappos, L., Oger, J., et al. (2000) · Nature Medicine · doi:10.1038/80525 · Cited by 512
Recent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512
Concannon, P., Rich, S. S., & Nepom, G. T. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0808284 · Cited by 510
Expanding antigen-specific regulatory networks to treat autoimmunity
Clemente-Casares, X., Blanco, J., Ambalavanan, P., Yamanouchi, J., Singha, S., Fandos, C., Tsai, S., Wang, J., Garabatos, N., Izquierdo, C., et al. (2016) · Nature · doi:10.1038/nature16962 · Cited by 510
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski, A., Ruhrmann, S., Faigle, W., Frauenknecht, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.011 · Cited by 508
Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion
Delong, T., Wiles, T. A., Baker, R. L., Bradley, B., Barbour, G., Reisdorph, R., Armstrong, M., Powell, R. L., Reisdorph, N., Kumar, N., et al. (2016) · Science · doi:10.1126/science.aad2791 · Cited by 503
Muraro, P. A., Douek, D. C., Packer, A., Chung, K., Guenaga, F. J., Cassiani-Ingoni, R., Campbell, C., Memon, S., Nagle, J. W., Hakim, F. T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041679 · Cited by 502
The heterogeneous pathogenesis of type 1 diabetes mellitus
Ilonen, J., Lempainen, J., & Veijola, R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0254-y · Cited by 494
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
The type I interferonopathies: 10 years on
Crow, Y. J., & Stetson, D. B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00633-9 · Cited by 489
Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome
Skopouli, F. N., Dafni, U., Ioannidis, J. P. A., & Moutsopoulos, H. M. (2000) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(00)80016-5 · Cited by 488
Host–microbiota interactions in immune-mediated diseases
Ruff, W. E., Greiling, T. M., & Kriegel, M. A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0367-2 · Cited by 487
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Fukaura, H., Kent, S. C., Pietrusewicz, M. J., Khoury, S. J., Weiner, H. L., & Hafler, D. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118779 · Cited by 473
Gold Nanoparticles: A Revival in Precious Metal Administration to Patients
Thakor, A. S., Jokerst, J., Zavaleta, C., Massoud, T. F., & Gambhir, S. S. (2011) · Nano Letters · doi:10.1021/nl202559p · Cited by 468
Epstein–Barr virus and multiple sclerosis
Soldan, S. S., & Lieberman, P. M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00770-5 · Cited by 467
Murphy, Á. C., Lalor, S. J., Lynch, M. A., & Mills, K. H. G. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.01.014 · Cited by 465
Eizirik, D. L., Sammeth, M., Bouckenooghe, T., Bottu, G., Sisino, G., Igoillo-Esteve, M., Ortis, F., Santin, I., Colli, M. L., Barthson, J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002552 · Cited by 465
Mechanisms maintaining peripheral tolerance
Mueller, D. L. (2010) · Nature Immunology · doi:10.1038/ni.1817 · Cited by 461
Karges, B., Schwandt, A., Heidtmann, B., Kordonouri, O., Binder, E., Schierloh, U., Boettcher, C., Kapellen, T., Rosenbauer, J., & Holl, R. W. (2017) · JAMA · doi:10.1001/jama.2017.13994 · Cited by 452
Couri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441
Foy, T. M., Laman, J. D., Ledbetter, J. A., Aruffo, A., Claassen, E., & Noelle, R. J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.157 · Cited by 440
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Marek-Trzonkowska, N., Myśliwiec, M., Dobyszuk, A., Grabowska, M., Techmańska, I., Juścińska, J., Wujtewicz, M. A., Witkowski, P., Młynarski, W., Balcerska, A., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0038 · Cited by 431
PD-1 and its ligands in T-cell immunity
Keir, M. E., Francisco, L. M., & Sharpe, A. H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.012 · Cited by 431
Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
Maugeri, M., Nawaz, M., Papadimitriou, A., Angerfors, A., Camponeschi, A., Na, M., Hölttä, M., Skantze, P., Johansson, S., Sundqvist, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12275-6 · Cited by 428
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 424
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
Scofield, R. H., Bruner, G. R., Namjou, B., Kimberly, R. P., Ramsey‐Goldman, R., Petri, M., Reveille, J. D., Alarcón, G. S., Vilá, L. M., Reid, J., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23701 · Cited by 417
A review on Lactococcus lactis: from food to factory
Song, A. A.-L., In, L. L. A., Lim, S. H. E., & Rahim, R. A. (2017) · Microbial Cell Factories · doi:10.1186/s12934-017-0669-x · Cited by 414
Hahn, J., Cook, N. R., Alexander, E. K., Friedman, S., Walter, J., Bubes, V., Kotler, G., Lee, I.-M., Manson, J. E., & Costenbader, K. H. (2022) · BMJ · doi:10.1136/bmj-2021-066452 · Cited by 414
Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands
Evavold, B. D., Sloan-Lancaster, J., & Allen, P. M. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90200-5 · Cited by 410
Sex differences in vaccine-induced humoral immunity
Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H., & Alter, G. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0726-5 · Cited by 410
Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients
Giannoukakis, N., Phillips, B., Finegold, D., Harnaha, J., & Trucco, M. (2011) · Diabetes Care · doi:10.2337/dc11-0472 · Cited by 407
Fassas, A., Anagnostopoulos, A., Kazis, A., Kapinas, K., Sakellari, I., Kimiskidis, V, & Tsompanakou, A. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700944 · Cited by 406
Higgins, P. J., & Weiner, H. L. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.2.440 · Cited by 405
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
Fugger, L., Jensen, L. T., & Rossjohn, J. (2020) · Cell · doi:10.1016/j.cell.2020.03.007 · Cited by 398
Getts, D. R., Martin, A. J., McCarthy, D. P., Terry, R. L., Hunter, Z. N., Yap, W. T., Getts, M. T., Pleiss, M., Luo, X., King, N. J., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2434 · Cited by 392
Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure
James, J. A., Neas, B. R., Moser, K. L., Hall, T., Bruner, G. R., Sestak, A. L., & Harley, J. B. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200105)44:5<1122::aid-anr193>3.0.co;2-d · Cited by 390
Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility
Xu, H., Li, X., Liu, D., Li, J., Zhang, X., Chen, X., Hou, S., Peng, L., Xu, C., Liu, W., et al. (2013) · Nature · doi:10.1038/nature12058 · Cited by 387
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Epstein-Barr Virus and Systemic Autoimmune Diseases
Houen, G., & Trier, N. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587380 · Cited by 379
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Fransson, M., Piras, E., Burman, J., Nilsson, B., Essand, M., Lu, B., Harris, R. A., Magnusson, P. U., Brittebo, E., & Loskog, A. S. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-112 · Cited by 372
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Therapeutic monoclonal antibodies
Breedveld, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)01034-5 · Cited by 359
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
Bobbin, M. L., & Rossi, J. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103633 · Cited by 353
Prediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346
Kinetics of skin resealing after insertion of microneedles in human subjects
Gupta, J., Gill, H. S., Andrews, S. N., & Prausnitz, M. R. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.05.021 · Cited by 342
Anti-CCP antibodies: the past, the present and the future
van Venrooij, W. J., van Beers, J. J. B. C., & Pruijn, G. J. M. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.76 · Cited by 341
Ishigaki, K., Sakaue, S., Terao, C., Luo, Y., Sonehara, K., Yamaguchi, K., Amariuta, T., Too, C. L., Laufer, V. A., Scott, I. C., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01213-w · Cited by 341
The Immune Response in Multiple Sclerosis
Rodríguez Murúa, S., Farez, M. F., & Quintana, F. J. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052920-040318 · Cited by 335
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
Karnell, J. L., Rieder, S. A., Ettinger, R., & Kolbeck, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.005 · Cited by 334
Kiriakidou, M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-7-201310010-01004 · Cited by 333
Progression of autoimmune diabetes driven by avidity maturation of a T-cell population
Amrani, A., Verdaguer, J., Serra, P., Tafuro, S., Tan, R., & Santamaria, P. (2000) · Nature · doi:10.1038/35021081 · Cited by 332
(PDWP), O. B. O. T. E. A. D. W. P. (. A. P. D. W. P., Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., Denton, C., Hawkey, C., Labopin, M., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.185 · Cited by 328
The geoepidemiology of Sjögren's syndrome
Mavragani, C. P., & Moutsopoulos, H. M. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.11.004 · Cited by 326
Metadata
- Authors
- Song, Y., Li, J., & Wu, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-10-04
- Volume
- 9
- Issue
- 1
- Pages
- 263-263
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4403086871
- Cited by
- 259
- References
- 633
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.